A strong dollar was just enough to bulk up second-quarter results at C.R. Bard Inc. (NYSE:BCR) as the surgical, vascular and oncology technology company out-muscled Wall Street expectations.
The Murray Hill, N.J.-based medical device company reported $124.6 million in second-quarter profits on $673.9 million in net sales. Earnings rose 11 percent over year-ago levels, reaching $1.29 a share, although after acquisition-related expenses and certain write-downs adjusted earnings grew to $1.39 a share, beating the consensus analyst forecast by 3 cents.